Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,574
  • Shares Outstanding, K 99,474
  • Annual Sales, $ 147,750 K
  • Annual Income, $ -284,230 K
  • 60-Month Beta 0.69
  • Price/Sales 0.31
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade FGEN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.58
  • Most Recent Earnings $-0.16 on 08/06/24
  • Next Earnings Date 11/04/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -179.86%)
  • Historical Volatility 97.80%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,142.70% on 01/22/24
  • IV Low 0.00% on 09/18/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 101
  • Volume Avg (30-Day) 185
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 39,100
  • Open Int (30-Day) 38,317

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.27
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.38
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +48.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3300 +27.27%
on 09/03/24
0.4852 -13.44%
on 09/16/24
+0.0545 (+14.91%)
since 08/16/24
3-Month
0.3300 +27.27%
on 09/03/24
1.5300 -72.55%
on 07/23/24
-0.6100 (-59.22%)
since 06/18/24
52-Week
0.3300 +27.27%
on 09/03/24
2.9300 -85.67%
on 02/12/24
-0.3700 (-46.84%)
since 09/18/23

Most Recent Stories

More News
FibroGen: Q2 Earnings Snapshot

FibroGen: Q2 Earnings Snapshot

FGEN : 0.4200 (-6.27%)
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...

RHHBY : 39.5100 (+0.46%)
ONCY : 0.9300 (-2.99%)
VSTM : 2.71 (-2.52%)
CADL : 7.76 (+10.39%)
FGEN : 0.4200 (-6.27%)
REGN : 1,138.81 (-0.69%)
ONC.TO : 1.28 (-1.54%)
The Fight Against Pancreatic Cancer: Biotech Firms Develop New Solutions for Rising Gen X Cases

USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
RHHBY : 39.5100 (+0.46%)
VSTM : 2.71 (-2.52%)
CADL : 7.76 (+10.39%)
FGEN : 0.4200 (-6.27%)
REGN : 1,138.81 (-0.69%)
Stock Index Futures Slip on Growth Fears, U.S. JOLTs Report in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.36%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.34% this morning after weak manufacturing data raised concerns about the U.S. economic health,...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
PARA : 10.56 (+1.15%)
NVDA : 113.37 (-1.92%)
BA : 155.11 (-0.82%)
SAIC : 134.51 (+0.34%)
FANG : 178.12 (-0.92%)
DVN : 40.37 (-0.22%)
CRWD : 267.12 (-0.60%)
FERG : 205.52 (-0.74%)
PVH : 96.30 (+0.15%)
HPE : 18.30 (+0.55%)
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected to Reach $7.4 Billion by 2032

USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
VSTM : 2.71 (-2.52%)
CTMX : 1.1900 (-1.65%)
BNTX : 115.62 (-7.29%)
FGEN : 0.4200 (-6.27%)
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...

ONCY : 0.9300 (-2.99%)
VSTM : 2.71 (-2.52%)
CTMX : 1.1900 (-1.65%)
BNTX : 115.62 (-7.29%)
FGEN : 0.4200 (-6.27%)
ONC.TO : 1.28 (-1.54%)
FibroGen: Q1 Earnings Snapshot

FibroGen: Q1 Earnings Snapshot

FGEN : 0.4200 (-6.27%)
FibroGen: Q4 Earnings Snapshot

FibroGen: Q4 Earnings Snapshot

FGEN : 0.4200 (-6.27%)
FibroGen: Q3 Earnings Snapshot

FibroGen: Q3 Earnings Snapshot

FGEN : 0.4200 (-6.27%)
Stocks Move Higher Before the Open as Investors Await Key U.S. GDP Data, Salesforce Earnings on Tap

September S&P 500 futures (ESU23) are up +0.06%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.07% this morning after three major U.S. benchmark indices rallied on Tuesday as soft economic...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
CTLT : 60.32 (-0.05%)
PDD : 98.23 (-0.15%)
VZ : 43.88 (-0.45%)
T : 21.73 (-0.23%)
CRM : 252.43 (-1.08%)
CRWD : 267.12 (-0.60%)
CHWY : 30.90 (-3.65%)
ORSTE.C.DX : 434.100 (-1.56%)
PRU.LN : 632.000 (+0.29%)
HPQ : 34.53 (+0.29%)

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 0.4840
2nd Resistance Point 0.4745
1st Resistance Point 0.4613
Last Price 0.4200
1st Support Level 0.4386
2nd Support Level 0.4291
3rd Support Level 0.4159

See More

52-Week High 2.9300
Fibonacci 61.8% 1.9368
Fibonacci 50% 1.6300
Fibonacci 38.2% 1.3232
Last Price 0.4200
52-Week Low 0.3300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar